Grace TherapeuticsGRCE -2.61%31 Forward PE Ratio is 0.00 as of Jul. 09, 2026. GuruFocus rates GRCE with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 354 Biotechnology companies, Grace Therapeutics ranks worse than 282485.59% on this metric.
Grace Therapeutics (NAS:GRCE) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Grace Therapeutics Forward PE Ratio Related Terms
Grace Therapeutics Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Grace Therapeutics's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grace Therapeutics Forward PE Ratio Chart
Grace Therapeutics Annual Data
Trend
Forward PE Ratio
Grace Therapeutics Quarterly Data
Forward PE Ratio
GRCE vs INMB, ABVC, NTRB: Forward PE Ratio Comparison
For the Biotechnology subindustry, Grace Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grace Therapeutics Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Grace Therapeutics's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Grace Therapeutics's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Grace Therapeutics (GRCE) has a Forward PE Ratio of 0.00 as of Jul. 09, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Grace Therapeutics and its competitors. According to the industry distribution chart, Grace Therapeutics ranks #999999 out of 354 companies in the Biotechnology industry.
Is Grace Therapeutics' Forward PE Ratio too high?
Grace Therapeutics' current Forward PE Ratio is 0.00. Based on the distribution chart, Grace Therapeutics ranks #999999 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Grace Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' Forward PE Ratio compare to INMB and ABVC?
According to the Biotechnology industry distribution chart, Grace Therapeutics ranks #999999 out of 354 companies for Forward PE Ratio. This places Grace Therapeutics in the lower half of its industry. The industry median Forward PE Ratio is 22.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.12, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Grace Therapeutics and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grace Therapeutics's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (GRCE) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Grace Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Grace Therapeutics (GRCE), the current Forward PE Ratio is 0.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score
Get the complete analysis for GRCE
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRCE has been successfully added to your 